BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14982764)

  • 1. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
    Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
    Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
    Mohapatra PR
    Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
    [No Abstract]   [Full Text] [Related]  

  • 5. Moxifloxacin treatment of tuberculosis.
    Gosling R; Gillespie S
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3642; author reply 3642-3. PubMed ID: 15328148
    [No Abstract]   [Full Text] [Related]  

  • 6. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
    Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
    Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
    Gosling RD; Uiso LO; Sam NE; Bongard E; Kanduma EG; Nyindo M; Morris RW; Gillespie SH
    Am J Respir Crit Care Med; 2003 Dec; 168(11):1342-5. PubMed ID: 12917230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
    Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
    J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
    Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
    Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin versus ethambutol in initial tuberculosis treatment.
    Chang KC; Leung CC
    Lancet; 2009 Jun; 373(9682):2197-8; author reply 2198-9. PubMed ID: 19560596
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin versus ethambutol in initial tuberculosis treatment.
    Sellier P; Delcey V; Raskine L; Sanson-Le-Pors MJ; Bergmann JF
    Lancet; 2009 Jun; 373(9682):2198; author reply 2198-9. PubMed ID: 19560598
    [No Abstract]   [Full Text] [Related]  

  • 19. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
    Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
    Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
    PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.